On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57ᵗʰ Participating Authority of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), marking a significant achievement for Jordan’s regulatory landscape and the local pharmaceutical industry. PIC/S

PIC/S is an international cooperative arrangement between pharmaceutical regulatory authorities that aims to strengthen Good Manufacturing Practice (GMP) standards and inspection systems worldwide. Membership signifies that a regulatory authority meets internationally recognized benchmarks in pharmaceutical inspection and quality oversight. PIC/S

JFDA’s accession followed a comprehensive pre-accession process, including a detailed paper review and an on-site assessment completed in April 2025. After endorsement by the PIC/S Sub-Committee on Compliance, full participation was unanimously approved by the PIC/S Committee at its meeting in Hong Kong in November 2025. PIC/S

What This Means for Jordan and Local Manufacturers

International Recognition: JFDA’s PIC/S membership confirms Jordan’s regulatory system aligns with global GMP standards, enhancing confidence in the quality and safety of Jordanian medicines. PIC/S
 

Facilitated Market Access: GMP certificates issued by JFDA will now be recognized by other PIC/S authorities, supporting export opportunities for Jordanian pharmaceutical products. PIC/S

Stronger Regulatory Cooperation: Participation in PIC/S fosters greater cooperation with global peers, access to joint inspection programs, and expanded training and capacity-building for pharmaceutical inspectors. PIC/S

This achievement reflects the ongoing commitment of JFDA in collaboration with industry partners to uphold the highest standards of pharmaceutical quality and regulatory excellence. It is a milestone that reinforces Jordan’s role as a trusted and competitive hub for pharmaceutical manufacturing in the region.